Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

680 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
US employment boom leaves factory workers behind
RE
Republicans hope to win Black voters for Trump. It won't be easy
RE
Zions Bancorporation N A : 2023 Annual Report Officers & Directors
PU
RELX : Notice of 2024 Annual General Meeting
PU
CORUS ENTERTAINMENT APPLAUDS ITS CREATIVE TEAMS AND PRODUCTION PARTNERS ON 65 CANADIAN SCREEN AWARDS NOMINATIONS
AQ
Johnson & Johnson - RYBREVANT in Combination with Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
AQ
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
PR
JELD-WEN Appoints Antonella Franzen to Board of Directors
PR
JELD-WEN Holding, Inc. Announces Board Changes
CI
The Trump voters in swing states who are returning to the fold
RE
The toll on migrants of a free bus north from the border
RE
Arcadium Lithium plc completed the acquisition of Allkem Limited (ASX : AKE) in a merger of equals transaction.
CI
Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
AQ
Voter advocates, conservative activists brace for 2024 election showdowns
RE
Johnson & Johnson's Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer
AQ
Asset manager GMO's first ETF will focus on 'quality' companies
RE
Johnson & Johnson : Phase 3 MARIPOSA-2 Study Shows RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56% and 52% in Patients with EGFR-Mutated NSCLC who Progressed on or after Osimertinib
PU
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
PU
Janssen Pharmaceutical - Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend toward Improvement in OS in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate plus Prednisone
AQ
Janssen Pharmaceutical - First Results with Erdafitinib-Releasing Intravesical Delivery System Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select FGFR Alterations
AQ
Janssen Pharmaceutical - Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer
AQ
Janssen Pharmaceutical - TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guerin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer
AQ
Janssen Pharmaceutical - First Results with Erdafitinib-Releasing Intravesical Delivery System Show Early Evidence of Positive Clinical Activity in Patients with Non-MuscleInvasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations
AQ
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC
PU
Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor
PU
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC
PU
Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor
PU
Johnson & Johnson : Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO
PU
Transcript : Accuray Incorporated - Analyst/Investor Day
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
PU
Janssen Pharmaceutical - Treatment with RYBREVANT and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer
AQ
Salesforce Gives $20M to Education, Expanding Pathways into Tech and AI Careers
BU
Janssen - Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT plus Chemotherapy
AQ
Johnson & Johnson : Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations
PU
Johnson & Johnson : Janssen Submits Supplemental Biologics License Application to the U.S. Food and Drug Administration Seeking Approval of RYBREVANT® (amivantamab-vmjw) in Combination with Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic EGFR Exon 20 Insertion Mutation-Positive Non Small Cell Lung Cancer
PU
The Cigna Group Foundation and YMCA Partner To Improve Community Vitality in Five Cities
PR
Transcript : Nanobiotix S.A. - Special Call
Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference
GL
Perspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conference
AQ
Janssen Pharmaceutical - New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT and Lazertinib Combination Therapy
AQ
McCarthy's moment: Debt ceiling vote secures Republican US House speaker's standing
RE
SEALED AIR CORP/DE : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Livent Corporation signed a definitive agreement to acquire Allkem Limited in a merger of equals transaction for $6.4 billion.
CI
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive Bladder Cancer
AQ
PFIZER INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Transcript : NRx Pharmaceuticals, Inc., Q4 2022 Earnings Call, Mar 30, 2023
ReFrame and IMDbPro Announce 2022 ReFrame Stamp Film Recipients
BU
RELX : Governance 23 February 2023
PU
Before facing Trump in 2024, DeSantis seeks wins on guns, abortion
RE
Comcast Signs Agreements with State of Indiana: Joint $50 Million Investment Will Bring Fiber Network to 10,000+ Rural Hoosiers Across 19 Counties
BU
No results for this search
  1. Stock Market
  2. Advanced search
  3. Suzanne Johnson
  4. News